register

News & Trends - Biotechnology

Brisbane-based Microba partners with UNSW Sydney’s Microbiome Research Centre to deliver world-class analysis

Health Industry Hub | September 25, 2019 |

Australia’s gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre (MRC) at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.

The collaboration between Microba and the MRC combines world-class microbiome analysis with leading clinicians and scientists, sharing a vision to not only discover new links with disease states, but with the ultimate goal of developing new diagnostics and therapies to help patients.

MRC held its official opening 12 August and will investigate how disturbance in the microbiome occurs and how it causes disease – a critical step in preventing it.

Microba co-founder and microbiome research pioneer, Professor Phil Hugenholtz welcomed the partnership, explaining that this opportunity would enable some of Australia’s best researchers to access the best analytical tools available.

“We hope that by furthering our knowledge of the gut microbiome, we will be able to improve the health and wellbeing of individuals. This collaboration allows all parties involved to contribute to this vision,” he said.

“With at least half of the population complaining of a digestive issue each year, high-powered research is essential to provide diagnostics and therapeutics into the future.”

Showcase your expertise and the value your business delivers, share industry-specific news, solutions, job ads and more with our subscribers. Contact us

The MRC is directed by UNSW Medicine Professor Emad El-Omar, a well recognised clinical gastroenterologist specialist with 20 years of gut microbiome research experience.  Professor El-Omar is also the Editor in Chief of the highly reputable journal, Gut.

“We are delighted to collaborate with Microba, a company underpinned by outstanding scientists at the cutting edge of research in the microbiome field,” he said.

“Our complementary strengths will deliver real benefits to patients the world over.

“The microbiome is an exciting new frontier in medicine and together we will harness its power to treat and prevent disease.”

You may also like Australian Biotech 2030 Vision to emerge from AusBiotech CEO Policy Forum


Human Resources

Decoding Novartis' blueprint for AI-powered workforce and a reimagined workplace: International HR Day 2025

Decoding Novartis’ blueprint for AI-powered workforce and a reimagined workplace: International HR Day

Health Industry Hub | May 16, 2025 |

As International HR Day (20 May) spotlights the theme HumanifyAI – Leading Change in a Dynamic World, Saada McNamee, Country […]

More


Medical and Science

What powers GenesisCare’s bold path in cancer research: Clinical Trials Day

What powers GenesisCare’s bold path in cancer research: Clinical Trials Day

Health Industry Hub | May 16, 2025 |

What does it take to deliver research that truly changes lives? For Sonya McColl, National Research Manager of Oncology at […]

More


News & Trends - MedTech & Diagnostics

Are we chasing value-based healthcare while ignoring the elephant in the hospital corridor?

Are we chasing value-based healthcare while ignoring the elephant in the hospital corridors?

Health Industry Hub | May 16, 2025 |

The health system is stuck in a volume-driven framework that rewards throughput over quality. It’s a model that no longer […]

More


News & Trends - MedTech & Diagnostics

Former APHA CEO joins day hospitals group amid strategic growth phase

Former APHA CEO joins day hospitals group amid strategic growth phase

Health Industry Hub | May 16, 2025 |

Cura Day Hospitals Group has announced the appointment of Michael Roff, former CEO of the Australian Private Hospitals Association (APHA), […]

More


This content is copyright protected. Please subscribe to gain access.